IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is Logos Global Management LP’s 4th Largest Position

Logos Global Management LP boosted its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 13.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,700,000 shares of the company’s stock after purchasing an additional 200,000 shares during the quarter. IDEAYA Biosciences comprises 4.8% of Logos Global Management LP’s portfolio, making the stock its 4th biggest holding. Logos Global Management LP owned 2.25% of IDEAYA Biosciences worth $59,687,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Franklin Resources Inc. grew its position in shares of IDEAYA Biosciences by 4.9% during the fourth quarter. Franklin Resources Inc. now owns 27,237 shares of the company’s stock valued at $969,000 after purchasing an additional 1,260 shares in the last quarter. TD Asset Management Inc raised its holdings in shares of IDEAYA Biosciences by 21.1% during the 4th quarter. TD Asset Management Inc now owns 137,690 shares of the company’s stock worth $4,899,000 after acquiring an additional 24,034 shares in the last quarter. Rafferty Asset Management LLC boosted its position in shares of IDEAYA Biosciences by 49.8% during the 4th quarter. Rafferty Asset Management LLC now owns 193,356 shares of the company’s stock valued at $6,880,000 after acquiring an additional 64,280 shares during the last quarter. Capital Research Global Investors boosted its position in shares of IDEAYA Biosciences by 43.6% during the 4th quarter. Capital Research Global Investors now owns 1,976,870 shares of the company’s stock valued at $70,337,000 after acquiring an additional 600,000 shares during the last quarter. Finally, Superstring Capital Management LP purchased a new position in shares of IDEAYA Biosciences in the fourth quarter valued at $8,941,000. 98.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on IDYA. Wedbush lowered their price objective on shares of IDEAYA Biosciences from $54.00 to $52.00 and set an “outperform” rating for the company in a research report on Tuesday, September 24th. JPMorgan Chase & Co. lowered their price target on shares of IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. BTIG Research boosted their price objective on IDEAYA Biosciences from $55.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. Citigroup dropped their target price on IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday, August 27th. Finally, Stifel Nicolaus increased their price target on IDEAYA Biosciences from $63.00 to $68.00 and gave the company a “buy” rating in a report on Tuesday, September 10th. Twelve analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $56.00.

IDEAYA Biosciences Trading Up 2.9 %

Shares of IDYA opened at $31.68 on Tuesday. The firm has a fifty day moving average price of $37.70 and a 200-day moving average price of $39.09. The firm has a market capitalization of $2.40 billion, a P/E ratio of -15.76 and a beta of 0.84. IDEAYA Biosciences, Inc. has a 12-month low of $23.41 and a 12-month high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.14). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 20.52%. During the same quarter in the previous year, the firm earned ($0.50) earnings per share. Analysts predict that IDEAYA Biosciences, Inc. will post -2.51 earnings per share for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.